LigoCyte’s lead product, a vaccine to prevent norovirus gastroenteritis, was developed by a proprietary virus-like particle platform (VLP) technology. It is in phase I/II of clinical development. Upfront payment is 60 million USD in cash.
Takeda press release, Oct. 5, 2012
Takeda Chemical Industries purchases US LigoCyte Pharmaceuticals, a vaccine company